【摘要】 目的:比较4种方案治疗2型糖尿病的成本-效果。方法:将2009-2010年入选的2型糖尿病患者随机分为A组(72例,阿卡波糖)、B组(72例,格列美脲)、C组(71例,二甲双胍)、D组(71例,瑞格列奈+二甲双胍)并进行治疗。评价其疗效并进行成本-效果分析。结果:治疗后,4组空腹血糖及餐后2h血糖的总有效率两两比较差异均无统计学意义(P>0.05);4组成本分别为798.32、258.54、184.55、210.32元;对空腹血糖的成本-效果比分别为942.53、310.37、225.89、240.92;对餐后2h血糖的成本-效果比分别为845.68、300.28、214.84、237.11;A、B、D组相对于C组对空腹血糖的增量成本-效果比分别为20459、4624.38、460.18,对餐后2h血糖的增量成本-效果比分别为7220.82、36995.00、920.36。结论:二甲双胍治疗2型糖尿病成本较低,但瑞格列奈联合二甲双胍控制2型糖尿病患者空腹血糖和餐后2h血糖的成本-效果比较优。更多还原

【Abstract】 OBJECTIVE:To compare the cost-effectiveness of four treatment schemes on type 2 diabetes mellitus.METHODS:Included type 2 diabetes mellitus patients during 2009-2010 were randomly divided into group A(72 cases,acarbose),group B(72 cases,glimepride),group C(71 case,metformin),group D(71 cases,repaglinide+metformin).Therapeutic efficacies of those groups were evaluated and cost-effect analysis was conducted.RESULTS:There was no statistical significance in the total effective rate of fasting blood glucose and 2 h blood glucose after meal among 4 groups after treatment(P>0.05).The costs of 4 groups were 798.32 yuan,258.54 yuan,184.55 yuan and 210.32 yuan,respectively.The cost-effectiveness ratios of fasting blood sugar were 942.53,310.37,225.89 and 240.92.The cost-effectiveness ratio of blood sugar 2 h after meal were 845.68,300.28,214.84 and 237.11;The incremental cost-effectiveness ratios of fasting blood glucose in group A,B,D were 20 459,4 624.38,460.18,compared with group C;The incremental cost-effectiveness ratios of blood glucose 2 h after meal were 7 220.82,36 995.00,920.36.CONCLUSION:The cost of metformin in the treatment of type 2 diabetes mellitus is low,but it is best to use repaglinide combined with metformin to control cost-effectiveness ratio of fasting blood glucose and blood glucose 2 h after meal.更多还原